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Abstract
When facial nerve axotomy (FNA) is performed on immunodeficient recombinase activating 
gene-2 knockout (RAG-2-/-) mice, there is greater facial motoneuron (FMN) death relative to wild 
type (WT) mice. Reconstituting RAG-2-/- mice with whole splenocytes rescues FMN survival after 
FNA, and CD4+ T cells specifically drive immune-mediated neuroprotection. Evidence suggests 
that immunodysregulation may contribute to motoneuron death in amyotrophic lateral sclerosis 
(ALS). Immunoreconstitution of RAG-2-/- mice with lymphocytes from the mutant superoxide 
dismutase (mSOD1) mouse model of ALS revealed that the mSOD1 whole splenocyte 
environment suppresses mSOD1 CD4+ T cell-mediated neuroprotection after FNA. The objective 
of the current study was to characterize the effect of CD4+ T cells on the central molecular 
response to FNA and then identify if mSOD1 whole splenocytes blocked these regulatory 
pathways.
Gene expression profiles of the axotomized facial motor nucleus were assessed from RAG-2-/- 
mice immunoreconstituted with either CD4+ T cells or whole splenocytes from WT or mSOD1 
donors. The findings indicate that immunodeficient mice have suppressed glial activation after 
axotomy, and cell transfer of WT CD4+ T cells rescues microenvironment responses. Additionally, 
mSOD1 whole splenocyte recipients exhibit an increased astrocyte activation response to FNA. In 
RAG-2-/- + mSOD1 whole splenocyte mice, an elevation of motoneuron-specific Fas cell death 
pathways is also observed. Altogether, these findings suggest that mSOD1 whole splenocytes do 
not suppress mSOD1 CD4+ T cell regulation of the microenvironment, and instead, mSOD1 
whole splenocytes may promote motoneuron death by either promoting a neurotoxic astrocyte 
phenotype or inducing Fas-mediated cell death pathways. This study demonstrates that peripheral 
immune status significantly affects central responses to nerve injury. Future studies will elucidate 
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the mechanisms by which mSOD1 whole splenocytes promote cell death and if inhibiting this 
mechanism can preserve motoneuron survival in injury and disease.
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1. Introduction
A growing body of literature indicates that peripheral immune status is an important factor 
in central nervous system responses to injury or disease (Beers et al., 2008; DeFrancesco-
Lisowitz et al., 2015; Ip et al., 2015; Spani et al., 2015). Using the facial nerve axotomy 
(FNA) model of peripheral nerve injury, our laboratory discovered that immunodeficient 
mice lacking functional B and T cells have significantly more facial motoneuron (FMN) 
death within the central nervous system (CNS) after FNA relative to wild type (WT) mice 
(Serpe et al., 1999; Serpe et al., 2000; Serpe et al., 2003). Immunoreconstitution of 
immunodeficient mice with WT whole splenocytes prior to FNA rescues FMN survival, and 
the CD4+ T cell population alone is specifically responsible for mediating neuroprotection 
after axotomy (Serpe et al., 2003). Key cellular elements within the facial motor nucleus that 
interact with peripheral neuroprotective CD4+ T cells include both astrocytes and microglia 
(Byram et al., 2004; Wainwright et al., 2009b; Wainwright et al., 2009c).
CD4+ T cells are implicated in amyotrophic lateral sclerosis (ALS), a neurodegenerative 
disease affecting motoneurons. CD4+ T cells are decreased in ALS patients relative to age-
matched controls (Chen et al., 2014), and patients with ALS exhibit increased peripheral 
immune activation and circulating cytokines (Chen et al., 2014; Lu et al., 2016). The mutant 
superoxide dismutase (mSOD1) mouse model of ALS also demonstrates significant 
immunodysregulation, including lymphopenia and a failure of T cells to generate a 
proliferation or immunization response to stimuli (Kuzmenok et al., 2006; Banerjee et al., 
2008). CD4+ T cell deficiency in mSOD1 mice results in accelerated disease progression, 
and adoptive cell transfer of WT CD4+ T cells into mSOD1 mice modestly improves 
survival (Banerjee et al., 2008; Beers et al., 2008). Thus, the immune system may be a new 
therapeutic target for ALS.
When FNA is superimposed on the mSOD1 mouse in the pre-symptomatic stages, FMN 
death after FNA mirrors that of immunodeficient mice, corroborating evidence for 
immunodysregulation in mSOD1 mice (Mariotti et al., 2002; Mesnard et al., 2011). These 
intriguing findings led us to explore the molecular changes that occur in the facial motor 
nucleus of both FMN and the surrounding neuropil in WT and mSOD1 mice (Mesnard et al., 
2011; Haulcomb et al., 2014). Genes associated with MN regeneration, glial activation, 
inflammation, and cell death were examined. While the FMN regenerative phenotype in 
mSOD1 mice was unaffected, astrocyte and microglia responses were found to be 
dysregulated by peripheral axotomy in mSOD1 mice. Furthermore, mSOD1 mice also 
exhibited increased expression of motoneuron-specific Fas cell death pathway components, 
indicating a disease-induced prevalence of Fas-mediated cell death (Haulcomb et al., 2014).
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We next explored the neuroprotective capacity of the mSOD1 peripheral immune system in 
immunodeficient mice. When whole splenocytes from mSOD1 mice, including CD4+ T 
cells, were transferred into RAG-2-/- mice, significant FMN death still occurred after FNA. 
However, when isolated mSOD1 CD4+ T cells were transferred into RAG-2-/- mice, we 
observed that FMN survival was rescued to WT levels (Mesnard-Hoaglin et al., 2014). 
These findings suggest that an inhibitory factor present in the mSOD1 whole splenocyte 
milieu blocks mSOD1 CD4+ T cell-mediated neuroprotection.
While we now have an understanding of the cellular elements involved in CD4+ T cell-
mediated prevention of FMN loss after target disconnection, the accompanying key 
molecular changes that occur in the CNS, and how they may factor in ALS, are unknown. 
The well-characterized nerve cell body response to injury in the facial nucleus provides the 
opportunity to exploit the advantages inherent in laser microdissection and qPCR in order to 
identify a CNS molecular signature modifiable by the peripheral immune system after injury 
(Lieberman, 1971; Grafstein, 1975; Moran & Graeber, 2004). This approach is both 
powerful and efficient because it captures large amounts of gene expression data reflecting 
different functional states and multiple cell types using a single method of tissue processing 
from individual animals.
The results indicate that the CNS astrocytic response to peripheral nerve injury appears to be 
differentially affected by peripheral immune status. Furthermore, mSOD1 immune cells 
induce Fas expression in the facial motor nucleus, which may contribute to motoneuron 
death. Collectively, these data suggest that cell-cell interactions between the CNS glia and 
adaptive immune are potential therapeutic targets in neurodegenerative diseases such as 
ALS.
2. Materials and Methods
2.1. Animals and surgical procedure
For this study, the following mouse strains were purchased from The Jackson Laboratory 
(Bar Harbor, ME) where they were bred and maintained in separate lines: C57BL/6J (WT, 
RRID:IMSR_JAX:000664), B6(Cg)-Rag2tm1.1Cgn/J (RAG-2-/-, RRID:IMSR_JAX:
008449), and B6.Cg-Tg(SOD1G93A)1Gur/J (mSOD1, RRID:IMSR_JAX:004435). WT and 
RAG-2-/-strains are maintained as homozygous inbred colonies. The mSOD1 strain is 
maintained by breeding a C57BL/6J female with a male hemizygous for the SOD1G93A 
mutation. All mice were obtained at 6 or 7 weeks of age and allowed to acclimate for 1 week 
prior to any manipulation. Female mice were exclusively used, which is a limitation of this 
study. Male mice were excluded because their propensity for aggression after surgery 
requires individual housing to prevent trauma and infection of the surgical site (Edwards, 
1968; Van Loo et al., 2003; Lockworth et al., 2015). Individual housing significantly stresses 
the animal, resulting in adverse effects on both immune physiology and animal welfare 
(Olsson & Westlund, 2007; Kamakura et al., 2016; Weber et al., 2017).
All animal procedures complied with National Institutes of Health guidelines on the care and 
use of laboratory animals and were approved by Indiana University School of Medicine's 
Institutional Animal Care and Use Committee. Mice were housed in sterilized microisolater 
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cages with a 12 hr light/dark cycle and fed autoclaved food pellets and drinking water ad 
libitum. The animal facility uses a laminar flow system to maintain a pathogen-free 
environment.
Aseptic procedures were followed during the FNA following National Institute of Health 
guidelines. FNA was performed on 8 week old mice following previously established 
methods (Olmstead et al., 2015). Briefly, mice were anesthetized with 2.5% isoflurane in 0.9 
L/min oxygen, and the facial nerve was exposed and transected at its exit from the 
stylomastoid foramen. The remaining nerve stumps were separated and resected to prevent 
reconnection. No operation was performed on the left facial nerve, allowing for the left 
facial motor nucleus to serve as a paired internal control. Prior to euthanasia, behavioral 
observations of ipsilateral facial paralysis verified that no functional recovery occurred.
2.2. Isolation and adoptive transfer of whole splenocytes and CD4+ T cells
Adoptive cell transfers were performed on recipient mice at 7 weeks of age, 1 week prior to 
FNA following a protocol modified from Serpe et al., 2003. Donor mice (1:1 donor:recipient 
ratio) were euthanized with CO2 inhalation followed by cervical dislocation. The spleen was 
dissected out and a single-cell suspension of whole splenocytes was generated following the 
Miltenyi Biotec gentleMACS protocol.
For preparation of whole splenocytes, red blood cell lysis was performed on the cell 
suspension with ACK Lysing Buffer (Thermo Fisher Scientific; A1049201) for 4 min at RT, 
and cells were washed and resuspended in PBS. 50 × 106 whole splenocytes in 100 μl of 
PBS were injected into the recipient mouse tail vein.
For preparation of CD4+ T cells, red blood cell lysis was not performed to maximize CD4+ 
T cell yield. The whole splenocyte cell pellet was incubated with CD4 (L3T4) MicroBeads 
(Miltenyi Biotec, 130-049-201) per manufacturer protocol, and magnetic separation was 
performed with the Possel_d2 program on an autoMACS™ Pro Separator. Cells were 
washed and resuspended in PBS, and 5 × 106 CD4+ T cells in 100 μl of PBS were injected 
into the recipient mouse tail vein. This cell number was selected based on data indicating 
that approximately 10% of whole splenocytes are CD4+ T cells in the C57BL/6J mouse 
strain (Laboratory).
CD4+ T cell fraction purity was measured using flow cytometry with FITC rat anti-mouse 
CD4 antibody (BD Biosciences Cat# 557307 RRID:AB_396633), and average purity levels 
were greater than 90% in accordance with previously published work from our laboratory 
(Serpe et al., 2003).
2.3. Laser capture microdissection
Experimental animals (n = 6-12/timepoint/group) were euthanized via CO2 inhalation 
followed by cervical dislocation at 7, 14, 28, and 56 days post-operation (dpo). An 
unoperated group was also included as a 0 dpo control. Brains were rapidly removed and 
immediately flash frozen, as described previously (Mesnard et al., 2010). 25 μm cryostat 
sections of the entire rostral-caudal extent of the facial nucleus within the brainstem were 
collected on Leica glass polyethylene foil membrane slides (Nuhsbaum, McHenry, IL, 
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11505158). Tissue staining and laser capture microdissection were performed using methods 
previously described (Mesnard et al., 2010). The right (axotomized, Ax) and left (control, C) 
facial motor nuclei were laser captured using a Leica ASLMD.
2.4. RNA extraction and reverse transcription
RNA extraction was performed per the Arcturus PicoPure® RNA Isolation Kit protocol 
(Thermo Fisher Scientific; KIT0204). RNA yield was quantified with a NanoDrop 2000 
Spectrophotometer. 60 ng of RNA was reverse transcribed into cDNA using the 
SuperScript® VILO cDNA Synthesis Kit and Master Mix following manufacturer 
instructions (Thermo Fisher Scientific; 11754050).
2.5. qPCR
qPCR was performed using an Eppendorf Realplex Mastercycler system. The 20 μl reaction 
volume contained 1 μl of cDNA, 1 μl of 20× TaqMan® FAM gene expression assay (Table 
1), 8 μl of 0.002% diethyl pyrocarbonate-treated water, and 10 μl of TaqMan Gene 
Expression Master Mix (Thermo Fisher Scientific; 4369016). The qPCR program was as 
follows: UDG optimization at 50°C for 2 min, AmpliTaq Gold Activation at 95°C for 10 
min, and 40 cycles of denaturation at 95°C for 15 sec followed by annealing/extension at 
60°C for 1 min.
We have previously established percent-changes in mRNA expression after axotomy using 
custom-made primers and SYBR® green reagents (Mesnard et al., 2010; Mesnard et al., 
2011; Haulcomb et al., 2014). We opted to use TaqMan assays in this study because of their 
enhanced sensitivity and specificity for gene targets (Alvarez & Done, 2014). To validate use 
of TaqMan assays, side-by-side comparisons of results were obtained using the SYBR and 
TaqMan systems. This comparison revealed that both SYBR and TaqMan yielded similar 
results for all genes of interest except Cd68 and Tnfr1 (data not shown). To maintain 
consistency with previously established results, custom primers and TaqMan probes were 
used for Cd68 (F 5′-CCCAAATTCAAATCCGAATCC-3′, R 5′-
GGTACCGTCACAACCTCC-3′, probe 5′-AAAGTGAGTGCGTCCCTTGCAGCC-3′) and 
Tnfr1 (F 5′-TGCCATGCAGGGTTCTTTCTG-3′, R 5′-
TTTGCAAGCGGAGGAGGTAGG-3′, probe 5′-
ACCCAATTCAGGGTGGAAGAAAGGT-3′).
2.6. Statistical analysis of qPCR data
The percent change in mRNA expression between axotomized and control facial motor 
nuclei was calculated using the Pfaffl method, with glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) as the reference gene (Pfaffl, 2001). Relative gene expression of 
Tnfα compared to Gapdh was used to quantify mRNA expression in the axotomized facial 
motor nucleus because there was no detectable expression of Tnfα in the control facial 
motor nucleus. The Grubbs' test was performed on the calculated values to detect and 
remove outliers (GraphPad QuickCalcs, www.graphpad.com, RRID:SCR_000306). 
Statistical significance was calculated using two-way ANOVA (factors: group × 
postoperative time, for each individual gene) followed by Student-Neuman-Keuls post hoc 
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multiple comparisons analysis with a significance level of p < 0.05 in SigmaPlot (SigmaPlot, 
version 13.0, https://systatsoftware.com/products/sigmaplot/, RRID:SCR_003210).
To validate that axotomy does not induce mRNA expression changes in the control facial 
motor nucleus, one-way ANOVA of the relative expression of each gene of interest 
compared to GAPDH within the control facial motor nucleus was performed at each 
postoperative timepoint with p < 0.05. For all genes examined, no statistically significant 
changes were detected (data not shown).
3. Results
3.1. Axotomy-induced pro-regeneration gene expression in WT, immunodeficient and WT 
CD4+ T cell immunoreconstituted facial motor nuclei
Axotomy-induced expression of βII-tubulin and growth-associated protein 43 (Gap-43) 
mRNA and protein by motoneurons is key to successful axonal elongation and target 
reconnection (Tetzlaff et al., 1991; Armstrong et al., 2008). These gene expression changes 
occur even when the axon is physically prevented from reconnecting to target, as is the case 
in this study (Mesnard et al., 2010).
Analysis of βII-tubulin mRNA expression in the experimental groups revealed that both 
group and postoperative time had significant effects (F2,75 = 4.07, p = 0.021; F4,75 = 68.98, p 
< 0.001, respectively). In the WT group, expression of βII-tubulin was significantly 
increased relative to unoperated controls at 7, 14, and 28 dpo (163 ± 12%, 168 ± 19%, and 
57 ± 15%, respectively; p < 0.05), and levels returned to baseline at 56 dpo. In the RAG-2-/- 
group, βII-tubulin expression was significantly elevated relative to unoperated controls at 7 
and 14 dpo (160 ± 21% and 178 ± 19%, respectively; p < 0.05), and expression was not 
different compared to baseline levels at 28 and 56 dpo. In the RAG-2-/- group with adoptive 
transfer of WT CD4+ T cells, βII-tubulin expression was significantly higher relative to 
unoperated controls at 7, 14, and 28 dpo (169 ± 13%, 171 ± 14%, and 96 ± 14%, 
respectively; p < 0.05), and expression reverted to uninjured levels at 56 dpo. No statistically 
significant differences were detected in the βII-tubulin gene expression response between 
WT and RAG-2-/- groups nor between WT and RAG-2-/- + WT CD4+ T cells groups. There 
was significantly higher βII-tubulin expression levels in RAG-2-/- + WT CD4+ mice 
compared to RAG-2-/- mice at 28 dpo (p = 0.026; Fig. 1A).
Comparison of Gap-43 mRNA expression in the experimental groups revealed that both 
group and postoperative time had significant effects (F2,80 = 10.48, p < 0.001; F4,80 = 
161.18, p < 0.001, respectively). In the WT group, expression of Gap-43 was significantly 
increased compared to unoperated controls at 7, 14, and 28 dpo (1083 ± 41%, 1239 ± 128%, 
and 351 ± 38%, respectively; p < 0.05), and expression returned to baseline levels at 56 dpo. 
In the RAG-2-/- group, Gap-43 expression was significantly elevated relative to unoperated 
controls at 7 and 14 dpo (873 ± 77% and 1057 ± 79%, respectively; p < 0.05), and 
expression was not different compared to baseline at 28 and 56 dpo. In the RAG-2-/- group 
with adoptive transfer of WT CD4+ T cells, Gap-43 expression was significantly higher 
relative to unoperated controls at 7, 14, and 28 dpo (1342 ± 81%, 1286 ± 92%, and 495 
± 79%, respectively; p < 0.05) and no different from control at 56 dpo. There were no 
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statistically significant differences in post-axotomy Gap-43 expression responses between 
WT and RAG-2-/- groups. The RAG-2-/- + WT CD4+ T cells group had a significant 
increase in Gap-43 expression relative to WT at 7 dpo (p = 0.038). The RAG-2-/- + WT 
CD4+ T cells group also had a statistically significant increase in Gap-43 expression 
compared to the RAG-2-/- group at 7, 14, and 28 dpo (p < 0.001, 0.020, and 0.004, 
respectively; Fig. 1B)
In summary, immunodeficiency does not affect the regenerative response of the axotomized 
FMN, and adoptive transfer of WT CD4+ T cells results in a modest increase in activation of 
the motoneuron regenerative program.
3.2. Axotomy-induced glial gene expression in WT, immunodeficient, and WT CD4+ T cell 
immunoreconstituted facial motor nuclei
Astrocytes and microglia play a key role after facial nerve injury, and their response to FNA 
has been well documented (Graeber et al., 1988; Tetzlaff et al., 1988). Astrocytes upregulate 
expression of glial fibrillary acidic protein (GFAP), a cytoskeletal protein, and microglia 
upregulate cluster of differentiation 68 (CD68), a lysosomal protein, as they respond to the 
FNA.
Examining Gfap mRNA expression in the experimental groups revealed that both group and 
postoperative time had significant effects (F2,76 = 9.88, p < 0.001; F4,76 = 47.09, p < 0.001, 
respectively), and there was significant interaction in group × postoperative time (F8,76 = 
3.56, p = 0.001). In the WT group, expression of Gfap was significantly increased relative to 
unoperated controls at 7, 14, 28, and 56 dpo (909 ± 97%, 805 ± 71%, 644 ± 121%, and 306 
± 45%, respectively; p < 0.05). In the RAG-2-/- group, Gfap expression was significantly 
elevated relative to unoperated controls at 7 and 14 dpo (782 ± 249% and 480 ± 79%, 
respectively; p < 0.05), and expression prematurely returned to baseline levels at 28 and 56 
dpo. In the RAG-2-/-group with adoptive transfer of WT CD4+ T cells, Gfap expression was 
significantly higher relative to unoperated controls at 7, 14, 28, and 56 dpo (646 ± 32%, 911 
± 31%, 763 ± 97%, and 236 ± 79, respectively; p < 0.05). There were statistically significant 
decreases in Gfap expression in the RAG-2-/- group relative to WT and RAG-2-/- + WT 
CD4+ T cells groups at 14 and 28 dpo (vs. WT: p = 0.029, 0.003, respectively; vs. RAG-2-/- 
+ WT CD4+ T cells: p < 0.001 at both timepoints). There were no statistically significant 
differences between the WT and RAG-2-/- + WT CD4+ T cell groups (Fig. 2A).
Comparison of Cd68 mRNA expression in the experimental groups revealed that both group 
and postoperative time had significant effects (F2,87 = 4.94, p = 0.009; F4,87 = 28.66, p < 
0.001, respectively). In the WT group, expression of Cd68 was significantly increased 
compared to unoperated controls at 7, 14, and 28 dpo (823 ± 109%, 772 ± 117%, 664 
± 78%, respectively; p < 0.05), and expression returned to baseline levels at 56 dpo. In the 
RAG-2-/- group, Cd68 expression was significantly elevated relative to unoperated controls 
at 7 and 14 dpo (541 ± 73%, 654 ± 28%, respectively; p < 0.05), and expression reverted to 
baseline levels at 28 and 56 dpo. In the RAG-2-/- group with adoptive transfer of WT CD4+ 
T cells, Cd68 expression was significantly higher relative to unoperated controls at 7, 14, 28, 
and 56 dpo (749 ± 93%, 810 ± 62%, 626 ± 104%, and 363 ± 103%, respectively; p < 0.05). 
There was a statistically significant decrease in Cd68 expression in the RAG-2-/- group 
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relative to WT at 28 dpo (p = 0.036). In addition, there were significantly decreased Cd68 
levels in the RAG-2-/- group relative to the RAG-2-/- + WT CD4+ T cells group at 28 and 56 
dpo (p = 0.011 and 0.037, respectively). There were no statistically significant differences 
between WT and RAG-2-/- + WT CD4+ T cells groups at any of the timepoints examined 
(Fig. 2B).
To further establish that facial nerve axotomy results in reactive glial changes, we performed 
a supplementary experiment evaluating mRNA changes for another marker of microglial 
activation, allograft inflammatory factor 1 (Aif1, the transcript name for ionized calcium 
binding adaptor Iba1), which revealed a similar pattern of expression in WT as Cd68 
(Supplemental Results, Fig. S1). We also evaluated GFAP and Iba1 protein expression 
changes in the WT axotomized facial motor nucleus and observed an increase in 
immunoreactivity for these markers at a time point corresponding to the peaks of their 
respective mRNA expression (Supplemental Results, Fig. S2), suggesting that our observed 
mRNA expression patterns reflect downstream protein changes.
Overall, immunodeficiency results in a significant decrease in both astrocyte and microglia 
activation responses to FNA, with the astrocyte reaction being more severely affected by 
immunodeficiency. Adoptive transfer of WT CD4+ T cells restores both astrocyte and 
microglia activation to WT levels at all post-axotomy timepoints, indicating that WT CD4+ 
T cells are key regulators of the glial response to FNA.
3.3. Axotomy-induced Tnf axis gene expression in WT, immunodeficient and WT CD4+ T 
cell immunoreconstituted facial motor nuclei
Tnfα is a proinflammatory cytokine that is necessary for microglia expression of αXβ2 
integrin, MHC I, and B7.2 costimulatory molecule expression after facial nerve injury 
(Raivich, 2002; Bohatschek et al., 2004a; Bohatschek et al., 2004b). Additionally, knocking 
out both TNFR1&2 simultaneously promotes motoneuron survival after facial nerve injury, 
suggesting that TNFα may have dual roles in immune-mediated neuroprotection (Raivich, 
2002). TNFR1 is a receptor that trimerizes after binding to TNFα and can either induce 
apoptosis via caspase 8 or trigger inflammatory gene expression via AP-1 and NF-κB (Baud 
& Karin, 2001; Wajant & Scheurich, 2011). Because of its association with cell death 
pathways, Tnfα and Tnfr1 expression were analyzed as possible contributors to the 
increased FMN death observed in RAG-2-/- mice. In addition, Tnfα served as a marker for 
the inflammatory status of the post-axotomy facial motor nucleus.
For all groups and timepoints, there was no detectable Tnfα expression in the control facial 
motor nucleus. Therefore, data shown is relative gene expression from the axotomized side 
only. Analysis of Tnfα mRNA expression in the experimental groups revealed that both 
group and postoperative time had significant effects (F2,74 = 19.78, p < 0.001; F4,74 = 18.12, 
p < 0.001, respectively), and there was significant interaction in group × postoperative time 
(F8,74 = 4.44, p < 0.001). In the WT group, Tnfα expression was significantly increased 
relative to unoperated controls at 7 and 14 dpo (4.4 ± 0.9 and 2.7 ± 1.0, respectively; p < 
0.05), and expression returned to baseline levels at 28 and 56 dpo. In the RAG-2-/- group, 
expression of Tnfα was not significantly different from unoperated controls at any of the 
observed timepoints. In the RAG-2-/- group with adoptive transfer of WT CD4+ T cells, 
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Tnfα expression was significantly higher relative to unoperated controls at 7, 14, and 28 dpo 
(3.3 ± 0.5, 5.6 ± 1.0, and 3.2 ± 0.7, respectively; p < 0.05), and levels reverted to baseline 
expression at 56 dpo. There were statistically significant decreases in Tnfα expression in the 
RAG-2-/- group relative to both WT and RAG-2-/- + WT CD4+ T cells groups at 7 dpo (p < 
0.001 for each). In addition, Tnfα expression was significantly decreased in the RAG-2-/- 
group compared to the RAG-2-/- + WT CD4+ T cells group at 14 and 28 dpo (p < 0.001 and 
p = 0.001, respectively) There were also statistically significant differences between the WT 
and RAG-2-/- + WT CD4+ T cell groups at 14 dpo (p = 0.004, Fig. 3A).
Comparison of Tnfr1 mRNA expression in the experimental groups revealed that both group 
and postoperative time had significant effects (F2,79 = 31.42, p < 0.001; F4,79 = 26.79, p < 
0.001, respectively), and there was significant interaction in group × postoperative time 
(F8,79 = 7.74, p < 0.001). In the WT group, expression of Tnfr1 was significantly increased 
compared to unoperated controls at 7 dpo (119 ± 31%, p < 0.05), and expression was not 
different from control at 14, 28, or 56 dpo. In the RAG-2-/- group, Tnfr1 expression was 
significantly elevated relative to unoperated controls at 14 dpo (139 ± 29%, p < 0.05), and 
expression was not significantly different from baseline at 7, 28, or 56 dpo. In the RAG-2-/- 
group with adoptive transfer of WT CD4+ T cells, Tnfr1 expression was significantly higher 
relative to unoperated controls at 7, 14, 28, and 56 dpo (219 ± 13%, 220 ± 15%, 135 ± 12%, 
and 73 ± 6%, respectively; p < 0.05). There were significant differences in Tnfr1 expression 
in comparing the WT and RAG-2-/- groups at 7 and 14 dpo (p < 0.001 and 0.029). In 
addition, there were statistically significant increased Tnfr1 levels in the RAG-2-/- + WT 
CD4+ T cells group compared to both WT and RAG-2-/- groups at 7, 14, and 28 dpo (vs. 
WT: p < 0.001, < 0.001, and 0.005, respectively; vs. RAG-2-/-: p < 0.001, 0.002, and 0.001, 
respectively; Fig. 3B).
In summary, there is decreased Tnfα expression and a delayed Tnfr1 response with 
immunodeficiency, and adoptive transfer of WT CD4+ T cells restores and increases both 
Tnfα and Tnfr1 expression. These results indicate that the immune system is an important 
regulator of the TNF axis in the CNS molecular response to FNA.
3.4. Axotomy-induced Fas/nNos cell death signaling pathway gene expression in WT, 
immunodeficient and WT CD4+ T cell immunoreconstituted facial motor nuclei
Motoneurons from mSOD1 mice are highly vulnerable to cell death via the Fas/neuronal 
nitric oxide synthase (nNos) cell death cascade (Raoul et al., 2002; Raoul et al., 2006). A 
study of cell death receptor expression on mSOD1 mice after FNA revealed that Fas/nNos 
signaling was highly expressed relative to WT, suggesting that the mSOD1 mutation leads to 
prominent expression of this cell death pathway (Haulcomb et al., 2014). Because Fas/nNos 
is related to motoneuron death after target disconnection in mSOD1 disease pathology, we 
wanted to explore if it played a role in the increased FMN death observed in 
immunodeficient animals.
Analysis of Fas mRNA expression in the experimental groups revealed that both group and 
postoperative time had significant effects (F2,84 = 5.30, p = 0.007; F4,84 = 7.93, p < 0.001, 
respectively). In the WT group, Fas expression was significantly increased relative to 
unoperated controls at 7, 14, 28, and 56 dpo (70 ± 12%, 62 ± 16%, 62 ± 16%, and 63 ± 21%, 
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respectively; p < 0.05). In the RAG-2-/- group, expression of Fas was not significantly 
different from unoperated controls at any of the observed timepoints. In the RAG-2-/- group 
with adoptive transfer of WT CD4+ T cells, Fas expression was not different from baseline 
at 7 and 14 dpo, and expression was significantly higher relative to unoperated controls at 28 
and 56 dpo (76 ± 14% and 84 ± 29%, respectively; p < 0.05). There was significantly higher 
expression of Fas in the WT group relative to the RAG-2-/- group at 7 and 14 dpo (p = 0.002 
and 0.043, respectively). Fas expression was also significantly higher in the WT group 
relative to RAG-2-/- + WT CD4+ T cells at 7 dpo (p = 0.004). Increased Fas expression was 
also observed in RAG-2-/- + WT CD4+ T cells compared to RAG-2-/- at 56 dpo (p = 0.006; 
Fig. 4A).
Comparison of nNos mRNA expression in the experimental groups revealed that both group 
and postoperative time had significant effects (F2,76 = 10.51, p < 0.001; F4,76 = 8.17, p < 
0.001, respectively). In the WT and RAG-2-/- groups, expression of nNos was not 
significantly different compared to unoperated controls at any of the examined timepoints. In 
the RAG-2-/-group with adoptive transfer of WT CD4+ T cells, nNos expression was 
significantly higher relative to unoperated controls at 56 dpo (92 ± 23%, p < 0.05). In 
comparing WT and RAG-2-/- groups, there was significantly different expression of nNos at 
28 dpo (p = 0.042). The RAG-2-/- + WT CD4+ T cells group has significantly higher nNos 
expression relative to both WT and RAG-2-/- groups at 56 dpo (p < 0.001 for both; Fig. 4B).
In summary, there is no evidence that the increased FMN death after FNA in 
immunodeficient RAG-2-/- mice is due to the Fas/nNos death cascade. Furthermore, WT 
CD4+ T cells do not significantly alter expression of components of the Fas death pathway 
except for the increased nNos observed at 56 dpo, a timepoint beyond the 28 dpo timepoint 
when maximum immune-mediated neuroprotection is observed.
3.5. Axotomy-induced pro-regenerative gene expression in immunodeficient mice with 
mSOD1 immunoreconstitution
The following set of experiments were designed to examine the differences in gene 
expression responses to axotomy between RAG-2-/- mice reconstituted with mSOD1 whole 
splenocytes or isolated CD4+ T cells. A WT whole splenocyte reconstitution group was 
included as an additional control for comparisons with the mSOD1 whole splenocyte group. 
The same genes as above were examined. The statistical analysis was conducted separately 
for these two experiments because this study was designed to address two separate, but 
related, questions.
Analysis of βII-tubulin mRNA expression in the experimental groups revealed that 
postoperative time had significant effects (F3,54 = 112.25, p < 0.001). In the RAG-2-/- group 
that received adoptive transfer of WT whole splenocytes, expression of βII-tubulin was 
significantly increased relative to unoperated controls at 7, 14, and 28 dpo (160 ± 12%, 216 
± 9%, and 127 ± 20%, respectively; p < 0.05), and levels returned to baseline at 56 dpo. In 
the RAG-2-/- group that received adoptive transfer of mSOD1 whole splenocytes, βII-tubulin 
expression was significantly elevated relative to unoperated controls at 7, 14, and 28 dpo 
(193 ± 34%, 206 ± 21%, and 113 ± 31%, respectively; p < 0.05), and expression was not 
different compared to control at 56 dpo. In the RAG-2-/- group with adoptive transfer of 
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mSOD1 CD4+ T cells, βII-tubulin expression was significantly higher relative to unoperated 
controls at 7, 14, and 28 dpo (162 ± 7%, 200 ± 19%, and 134 ± 9%, respectively; p < 0.05), 
and expression reverted to uninjured levels at 56 dpo. In comparing whole splenocyte 
recipient groups, there were no statistically significant differences in the βII-tubulin gene 
expression response between RAG-2-/- mice reconstituted with WT or mSOD1 whole 
splenocytes. In addition, there were no differences in βII-tubulin expression between 
mSOD1 whole splenocyte or mSOD1 CD4+ T cell recipients. In comparing RAG-2-/- + WT 
whole splenocyte and RAG-2-/- + mSOD1 CD4+ T cell groups, there was a significant 
difference in βII-tubulin expression at 7 dpo (p = 0.036, Fig. 5A).
Comparison of Gap-43 mRNA expression in the experimental groups revealed that both 
group and postoperative time had significant effects (F2,55 = 4.62, p = 0.014; F3,55 = 32.06, p 
< 0.001). In the RAG-2-/- group that received adoptive transfer of WT whole splenocytes, 
expression of Gap-43 was significantly increased relative to unoperated controls at 7, 14, 
and 28 dpo (1552 ± 129%, 2064 ± 258%, and 1075 ± 305%, respectively; p < 0.05), and 
levels returned to baseline at 56 dpo. In the RAG-2-/- group that received adoptive transfer of 
mSOD1 whole splenocytes, Gap-43 expression was significantly elevated relative to 
unoperated controls at 7, 14, and 28 dpo (3412 ± 662%, 2845 ± 470%, and 1370 ± 373%, 
respectively; p < 0.05), and expression was not different compared to baseline at 56 dpo. In 
the RAG-2-/- group with adoptive transfer of mSOD1 CD4+ T cells, Gap-43 expression was 
significantly higher relative to unoperated controls at 7 and 14 dpo (2122 ± 293% and 3064 
± 395%, respectively; p < 0.05), and expression reverted to uninjured levels at 28 and 56 
dpo. In comparing whole splenocyte recipient groups, there was a statistically significant 
difference in the Gap-43 gene expression response between RAG-2-/- mice reconstituted 
with WT or mSOD1 whole splenocytes at 7 dpo (p = 0.002). In addition, there was a 
significant difference in Gap-43 expression between mSOD1 whole splenocyte and mSOD1 
CD4+ T cell recipients at 7 dpo (p = 0.019). In comparing RAG-2-/- + WT whole splenocyte 
and RAG-2-/- + mSOD1 CD4+ T cell groups, there was a significant difference in Gap-43 
expression at 14 dpo (p = 0.008, Fig. 5B).
Overall, there were no significant differences in motoneuron regeneration-associated gene 
expression between mSOD1 and WT whole splenocyte recipients, except for increased 
Gap-43 expression in the early post-axotomy timepoints. In addition, the mSOD1 whole 
splenocyte and mSOD1 CD4+ T cell recipients exhibited similar neuroregenerative 
responses, indicating that mSOD1 whole splenocytes do not have a deleterious effect on the 
axotomized FMN.
3.6. Axotomy-induced glial gene expression in immunodeficient mice with mSOD1 
immunoreconstitution
Analysis of Gfap mRNA expression in the experimental groups revealed that postoperative 
time had significant effects (F3,54 = 5.76, p = 0.002). All three groups exhibited a significant 
increase in Gfap expression relative to uninjured controls at 7, 14, 28, and 56 dpo (RAG-2-/- 
+ WT whole splenocytes: 2234 ± 213%, 2313 ± 255%, 2175 ± 435%, and 1492 ± 4%; 
RAG-2-/- + mSOD1 whole splenocytes: 2205 ± 178%, 2681 ± 572%, 2080 ± 446%, and 
1116 ± 254%; RAG-2-/- + mSOD1 CD4+ T cells: 2203 ± 385%, 3138 ± 270%, 2969 
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± 313%, and 1859 ± 515%, respectively; p < 0.05). Comparing all three experimental groups 
reveals no significant differences in Gfap expression after axotomy (Fig. 6A).
Examination of Cd68 mRNA expression in the experimental groups revealed that 
postoperative time had significant effects (F3,54 = 11.68, p < 0.001). For all three groups, 
Cd68 expression was significantly increased relative to unoperated controls at 7, 14, 28, and 
56 dpo (RAG-2-/- + WT whole splenocytes: 811 ± 55%, 606 ± 49%, 636 ± 92%, and 402 
± 106%; RAG-2-/- + mSOD1 whole splenocytes: 857 ± 155%, 925 ± 125%, 920 ± 207%, 
and 361 ± 76%; RAG-2-/- + mSOD1 CD4+ T cells: 772 ± 127%, 725 ± 37%, 1063 ± 99%, 
and 335 ± 63%, respectively; p < 0.05; Fig. 6B). There was a significant difference in Cd68 
expression at 28 dpo between the RAG-2-/- + mSOD1 CD4+ T cell and WT whole 
splenocyte recipients (p = 0.002). There were no other significant differences of Cd68 
responses between the groups at any of the observed timepoints (Fig. 6B).
To summarize, the astrocyte and microglia reaction to FNA were similar between the WT 
and mSOD1 whole splenocyte recipients, as well as between the mSOD1 whole splenocyte 
and mSOD1 CD4+ T cells recipients, indicating that mSOD1 whole splenocytes do not 
negatively impact the glial response to axotomy. There is a notable increase in astrocyte 
activation in these three group relative to the WT group (Fig. 2A).
3.7. Axotomy-induced TNF axis gene expression in immunodeficient mice with mSOD1 
immunoreconstitution
Analysis of Tnfα mRNA expression in the experimental groups revealed that postoperative 
time had significant effects (F3,61 = 10.63, p < 0.001), and there was a significant interaction 
between group × postoperative time (F9,61 = 2.53, p = 0.016). In the RAG-2-/- group that 
received adoptive transfer of WT whole splenocytes, expression of Tnfα was significantly 
increased relative to unoperated controls at 7 and 28 dpo (2.7 ± 0.7 and 3.5 ± 1.2, 
respectively; p < 0.05), and levels were not different from baseline at 14 and 56 dpo. Both 
RAG-2-/- + mSOD1 whole splenocytes and mSOD1 CD4+ T cells groups have significantly 
increased Tnfα expression compared to unoperated controls at 7, 14, and 28 dpo (RAG-2-/- 
+ mSOD1 whole splenocytes: 2.2 ± 0.6, 2.7 ± 1.3, and 3.7 ± 0.4; RAG-2-/- + mSOD1 CD4+ 
T cells: 2.3 ± 0.2, 2.3 ± 0.3, 3.1 ± 0.8, respectively; p < 0.05). Comparing all three 
experimental groups reveals no significant differences in Tnfα expression after axotomy 
(Fig. 7A).
Comparison of Tnfr1 mRNA expression in the experimental groups revealed that 
postoperative time had significant effects (F3,54 = 17.35, p < 0.001). For all three groups, 
Tnfr1 expression was significantly increased relative to unoperated controls at 7, 14, 28, and 
56 dpo (RAG-2-/- + WT whole splenocytes: 84 ± 2%, 96 ± 4%, 86 ± 17%, and 34 ± 8%; 
RAG-2-/- + mSOD1 whole splenocytes: 108 ± 5%, 102 ± 13%, 95 ± 13%, and 44 ± 9%; 
RAG-2-/- + mSOD1 CD4+ T cells: 88 ± 7%, 102 ± 11%, 91 ± 16%, and 52 ± 9%, 
respectively; p < 0.05). There were no significant differences in Tnfr1 expression between 
the three groups at any of the observed timepoints (Fig. 7B).
The data demonstrate that Tnfα/Tnfr1 expression after FNA was equivalent between the WT 
and mSOD1 whole splenocyte recipients, as well as between the mSOD1 whole splenocyte 
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and mSOD1 CD4+ T cells recipients, indicating that mSOD1 whole splenocytes do not 
affect the axotomy-induced TNF axis response.
3.8. Axotomy-induced Fas/nNos cell death signaling pathway gene expression in 
immunodeficient mice with mSOD1 immunoreconstitution
Analysis of Fas mRNA expression in the experimental groups revealed that group and 
postoperative time had significant effects (F2,54 = 6.01, p = 0.004; F3,54 = 14.92, p < 0.001), 
and there was a significant interaction between group × postoperative time (F6,54 = 2.58, p = 
0.029). In the RAG-2-/- group that received adoptive transfer of WT whole splenocytes, 
expression of Fas was not significantly different from unoperated controls at any of the 
examined timepoints. In the RAG-2-/- group that received adoptive transfer of mSOD1 
whole splenocytes, Fas expression was significantly elevated relative to unoperated controls 
at 7, 14, 28, and 56 dpo (72 ± 23%, 55 ± 9%, 133 ± 23%, and 82 ± 9%, respectively; p < 
0.05). In the RAG-2-/- group with adoptive transfer of mSOD1 CD4+ T cells, Fas expression 
remained at baseline levels at 7 and 14 dpo, then increased significantly relative to 
unoperated controls at 28 and 56 dpo (191 ± 32% and 81 ± 15%, respectively; p < 0.05). In 
comparing the WT and mSOD1 whole splenocyte recipient groups, there were statistically 
significant differences in Fas gene expression at 7 and 28 dpo (p = 0.025 and 0.013, 
respectively). Additionally, there was a significant difference between RAG-2-/- + WT whole 
splenocyte and mSOD1 CD4+ T cell recipients at 28 dpo (p < 0.001). There was also a 
significant increase in Fas expression at 28 dpo between mSOD1 CD4+ T cell recipients 
compared to mSOD1 whole splenocyte recipients (p = 0.038; Fig. 8A).
Comparison of nNos mRNA expression in the experimental groups revealed that 
postoperative time had significant effects (F3,54 = 3.83, p = 0.015). In the RAG-2-/- group 
that received adoptive transfer of WT whole splenocytes or mSOD1 CD4+ T cells, 
expression levels of nNos were not significantly different from unoperated controls at any of 
the examined timepoints. In the RAG-2-/- group that received adoptive transfer of mSOD1 
whole splenocytes, nNos expression was significantly elevated relative to unoperated 
controls at 56 dpo (62 ± 20, p < 0.05). In comparing WT and mSOD1 whole splenocyte 
recipient groups, there were no statistically significant differences in the nNos gene 
expression response. There was a significant difference in nNos expression at 14 dpo 
between RAG-2-/- + WT whole splenocyte and RAG-2-/-+ mSOD1 CD4+ T cell groups (p = 
0.031). Comparing RAG-2-/- groups that received adoptive cell transfer of mSOD1 whole 
splenocytes or mSOD1 CD4+ T cells reveals significant differences in nNos expression at 7 
and 56 dpo (p = 0.030 and 0.020, respectively; Fig. 8B).
After FNA, both mSOD1 whole splenocytes and mSOD1 CD4+ T cell recipients have 
elevated central Fas expression at 28 dpo, and mSOD1 whole splenocytes also increased Fas 
at 7 dpo compared to WT whole splenocytes. nNos expression was also increased in 
mSOD1 whole splenocyte recipients at 7 and 56 dpo relative to mSOD1 CD4+ T cell 
recipients. Together, these findings indicate that the mSOD1 gene mutation restricted to the 
peripheral immune system compartment results in aberrant induction of Fas/nNos expression 
after FNA, potentially leading to increased FMN death after target disconnection.
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4. Discussion
4.1. Summary of findings
Historically, the CNS response to peripheral target disconnection has been well-
characterized and collectively described as the “axon reaction” and/or “nerve cell body 
response to injury” (Lieberman, 1971; Grafstein, 1975). Using a variety of techniques, 
including in situ hybridization, PCR, protein quantitation, and immunohistochemistry, 
coordinated neuronal/glial RNA and protein changes have been documented in the facial 
nerve injury model in particular and were verified here in additional control experiments that 
are presented in the supplementary data section (Figs. S1 and 2). In the present study, we 
capitalized on this wealth of foundational literature in the design and utilization of laser 
capture microdissection and qPCR to examine the impact of immunodeficiency on gene 
expression in the facial motor nucleus after peripheral target disconnection. While the 
phenotypic MN response to nerve injury was not altered, astrocytic and microglial responses 
were specifically affected by peripheral immune status. Importantly, elevated Fas gene 
expression within the facial nucleus after axotomy occurred with reconstitution using 
immune cells from the mSOD1 mice, suggesting a unique immune defect capable of 
inducting motoneuron-specific central death mechanisms.
4.2. Intrinsic motoneuron molecular response to injury is not affected by peripheral 
immunestatus
4.2.1. CD4+ T cell-mediated neuroprotection does not occur via regulation of 
motoneuron regeneration-associated gene expression—To determine if CD4+ T 
cells acted directly on the motoneuron to promote neuronal survival after axotomy, we 
examined the effects of peripheral immune status on the motoneuron cell body response to 
axotomy. Neither immunodeficiency nor reconstitution with WT CD4+ T cells resulted in 
significant changes in the motoneuron gene expression response to axotomy, indicating that 
the motoneuron molecular response occurs independent from the peripheral immune system. 
Further evidence that motoneuron regeneration after axotomy is unaffected by peripheral 
immune status can be found in studies using crush axotomy, in which slowed, but complete, 
functional recovery is observed in immunodeficient or immunosuppressed mice (Lieberman 
et al., 2011; Bombeiro et al., 2016). In both crush and cut axotomies, significantly more 
motoneuron death is observed in immunodeficient and immunosuppressed mice, despite the 
regenerative efforts of the motoneuron (Serpe et al., 1999; Beahrs et al., 2010; Lieberman et 
al., 2011). This incongruency between the motoneuron regeneration response and cell body 
survival supports the concept that factors extrinsic to the motoneuron are responsible for 
determining motoneuron survival after injury.
4.2.2. mSOD1 whole splenocytes do not negatively affect motoneuron 
regeneration-associated gene expression—The failure of mSOD1 whole 
splenocytes to confer neuroprotection in immunodeficient mice, despite their containing 
neuroprotective mSOD1 CD4+ T cells, led us examine how neuroregenerative molecular 
responses to axotomy were affected by mSOD1 whole splenocytes. Overall, mSOD1 whole 
splenocyte recipients exhibited a similar motoneuron regeneration-associated gene 
expression response relative to WT whole splenocyte and mSOD1 CD4+ T cell recipients, 
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indicating that mSOD1 whole splenocytes do not have a negative effect on the motoneuron 
response to axotomy. This finding corroborates molecular data gathered from axotomized 
mSOD1 mice, which also demonstrate WT-levels of regeneration-associated gene expression 
after axotomy but significantly greater motoneuron death (Mariotti et al., 2002; Mesnard et 
al., 2011; Kawamura et al., 2012; Haulcomb et al., 2014). Similar to immunodeficient mice, 
mSOD1 mice have delayed, but complete, functional recovery after a crush axotomy, 
suggesting that the intrinsic neuroregeneration response to axotomy is also intact in the 
context of motoneuron disease (Mesnard et al., 2013).
These results collectively indicate that the axotomy-induced motoneuron regeneration 
response is an intrinsic program executed by the motoneuron that is not affected by 
motoneuron disease or peripheral immune status. Additionally, this disconnect between 
increased motoneuron death and intact neuroregenerative responses supports the claim that 
extrinsic, not intrinsic, components dictate motoneuron survival after injury.
4.3. Extrinsic glial molecular response to injury is significantly affected by peripheral 
immune status
4.3.1. WT CD4+ T cells are responsible for sustaining the glial activation 
response to axotomy—In examining the effects of immune status on astrocyte and 
microglia gene expression after axotomy, it was discovered that in immunodeficient mice, 
glial activation is initially intact, however prematurely falls to baseline levels relative to WT. 
The astrocyte reaction is more sensitive to immune status because their decreased activation 
is observed at both middle and late post-axotomy timepoints, whereas decreased microglia 
activation is observed only at a later timepoint. Adoptive transfer of WT CD4+ T cells fully 
restores astrocyte and microglia activation to WT levels, signifying that the peripheral 
immune system regulates central glial activation after axotomy.
Our findings of intact early glial responses to injury are in agreement with the literature 
describing that initiation of the glial reaction occurs in response to electrical signals, purine 
release, and cytokine signaling from the injured motoneuron cell body (Grafstein, 1975; 
Streit et al., 2000; Castellano et al., 2016). The timing of the loss of glial activation at middle 
and late timepoints correlates with peak production of TH2-inducing cytokines and 
maximum T cell presence found by other studies of the post-axotomy facial motor nucleus 
(Raivich et al., 1998; Wainwright et al., 2009a; Almolda et al., 2014). This glial activation 
by CD4+ T cells may occur in response to the secondary reactivation of CD4+ T cells by 
APCs in the CNS (Aloisi et al., 1999; Carson et al., 1999; Byram et al., 2004).
The sensitivity of astrocyte activation to the lack of CD4+ T cells is evident in other 
neurodegenerative disease models. For example, decreased astrogliosis and unaffected 
microgliosis is observed in a RAG-2-/-/PSAPP (presenilin 1/amyloid precursor protein) 
transgenic mouse model of Alzheimer's disease (Spani et al., 2015). A similar pattern of 
decreased astrocyte and intact microglia activation is observed in CD4-/- mice after spinal 
nerve L5 transection (Cao & DeLeo, 2008). Microglia in severe combined immunodeficient 
(scid) mice form more phagocytic clusters and have decreased expression of MHC I antigen-
presenting molecules in response to FNA, demonstrating that some microglia responses are 
reliant upon the adaptive arm of the immune system (Bohatschek et al., 2004a). Altogether, 
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our results, combined with findings in the literature, lead us to conclude that the central glial 
reaction to peripheral nerve injury is reliant upon CD4+ T cells.
4.3.2. mSOD1 whole splenocytes do not inhibit mSOD1 CD4+ T cell regulation 
of the glial activation response, but may differentially induce a neurotoxic glial 
phenotype—Previous studies identified that mSOD1 mice exhibit decreased glial reaction 
relative to WT mice after FNA, similar to what is observed in immunodeficient RAG-2-/- 
mice in the first half of this study (Mesnard et al., 2011; Haulcomb et al., 2014). These 
results led us to hypothesize that mSOD1 whole splenocytes would inhibit the ability of 
mSOD1 CD4+ T cells to regulate the glial response to injury. To our surprise, glial 
activation in mSOD1 whole splenocyte recipients were similar to WT whole splenocyte and 
mSOD1 CD4+ T cell recipients, leading us to reject our original hypothesis. In fact, a 
significant augmentation of the axotomy-induced astrocyte response was observed in these 
three experimental groups relative to WT and WT CD4+ T cell recipient groups, supporting 
the concept that astrocytes are acutely sensitive to peripheral immune status.
Future experiments will further characterize the phenotypic responses of astrocytes and 
microglia to FNA because Gfap and Cd68 gene expression are pan-activation markers of 
glial responses (Laskawi & Wolff, 1996; Brettschneider et al., 2012). Examination of the 
astrocyte phenotypic response is of particular importance to future work given the significant 
effects peripheral immune status has on astrocyte reaction to FNA. Recent transcriptomic 
analyses of astrocytes in different neurological disease contexts identified neurotoxic A1 and 
neuroprotective A2 astrocyte phenotypes (Zamanian et al., 2012; Liddelow et al., 2017). 
These studies, in conjunction with our data, lead us to hypothesize that mSOD1 whole 
splenocytes may promote the neurotoxic A1 phenotype, whereas mSOD1 CD4+ T cells 
promote the neuroprotective A2 phenotype, and this differential regulation of astrocytic 
phenotype may be a key determinant of motoneuron survival after axotomy.
4.4. A novel role for TNFα signaling in the post-axotomy facial motor nucleus
4.4.1. WT CD4+ T cells may regulate glial microenvironment responses using 
the TNFa signaling pathway—Because immunodeficient mice have greater motoneuron 
death after axotomy, expression of Tnfα/Tnfr1 was analyzed in this study because previous 
studies identified that TNFα is associated with FMN death after FNA (Terrado et al., 2000; 
Raivich, 2002). In this study, immunodeficient mice demonstrated a decreased Tnfα and 
delayed Tnfr1 response, suggesting that TNFα signaling is not contributing to the increased 
motoneuron death observed in this group. Furthermore, WT CD4+ T cells both restored and 
augmented Tnfα expression, and also elicited a significant increase in Tnfr1 expression 
relative to both WT and immunodeficient mice, leading us to conclude that CD4+ T cells 
may regulate glial microenvironment responses via the TNFα/TNFR1 signaling pathway. 
This signaling pathway is important for regulation of cytokine production and inflammatory 
responses (Baud & Karin, 2001; McCoy & Tansey, 2008; Wajant & Scheurich, 2011). In the 
CNS, TNFα promotes astrocyte connectivity, and it also regulates nitric oxide production 
and antigen presentation by microglia (Hensley, 2003; Almad et al., 2016) (Bohatschek et 
al., 2004a). Altogether, we conclude that WT CD4+ T cells potentially utilize the TNF 
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signaling axis to regulate glial responses to peripheral nerve axotomy to promote 
motoneuron survival.
4.4.2. mSOD1 whole splenocytes do not induce TNF-mediated cell death in the 
post-axotomy facial motor nucleus—TNFα can have both beneficial and harmful 
roles in the CNS, and in the context of the mSOD1 mouse model, neuroinflammation is 
observed early in disease pathology and is associated with greater motoneuron death 
(Alexianu et al., 2001; Hensley et al., 2002; Hensley, 2003; Chen et al., 2004). In the control 
facial motor nucleus of mSOD1 mice, constitutive expression of Tnfα is observed as early 
as postnatal day 59, and FMN death from disease alone is observed as early as postnatal day 
112 (Mesnard et al., 2011; Haulcomb et al., 2014). In this study, we examined if mSOD1 
whole splenocytes promoted FMN death after FNA by induction of the TNFα/TNFR1 death 
pathway. First, neither mSOD1 whole splenocytes nor mSOD1 CD4+ T cells induced Tnfα 
expression in the control facial motor nucleus, suggesting that the constitutive TNFα 
observed in mSOD1 mice is not induced by the peripheral immune system. After axotomy, 
there were no differences in Tnfα/Tnfr1 expression when comparing mSOD1 whole 
splenocyte, WT whole splenocyte, and mSOD1 CD4+ T cell recipient groups, indicating 
that mSOD1 whole splenocytes do not utilize this signaling pathway to promote motoneuron 
death. To summarize, the TNF signaling axis is not associated with motoneuron death 
induced by mSOD1 whole splenocytes.
4.5. mSOD1 disease mutation restricted to the peripheral immune compartment induces 
central Fas/nNos expression
4.5.1. Fas/nNos-mediated motoneuron death is not associated with axotomy-
induced motoneuron death in immunodeficient mice—Fas and Fas ligand (FasL) 
are ubiquitously expressed in the CNS and are utilized to prevent autoimmune reactions in 
the brain (Flugel et al., 2000; Becher et al., 2006). Fas and FasL can also induce neuronal 
death in the context of many different neurological diseases, and it is highly associated with 
pathological motoneuron death in the mSOD1 mouse model of ALS (Raoul et al., 2002; 
Choi & Benveniste, 2004; Raoul et al., 2006; Locatelli et al., 2007). Downstream signaling 
from Fas can activate nNos, a neuron-specific terminal step of Fas-mediated cell death in the 
CNS (Raoul et al., 2002).
When the Fas/nNos death pathway was examined in immunodeficient mice, there were no 
significant increases in expression of either of these death pathway components. WT CD4+ 
T cells also did not significantly alter expression of these molecules in the post-axotomy 
timecourse. Altogether, these results indicate that the increased axotomy-induced 
motoneuron death in immunodeficient mice is not due to the Fas cell death pathway, and is 
likely the result of dysregulation of extrinsic factors that promote motoneuron survival.
4.5.2. mSOD1 whole splenocytes and mSOD1 CD4+ T cells significantly 
increase expression of Fas—mSOD1 mice have a significant upregulation of the Fas/
nNos death pathway after axotomy, providing further evidence that Fas-induced cell death 
may be an important contributor to disease pathology (Haulcomb et al., 2014). In examining 
Fas expression in this study, both mSOD1 whole splenocyte and mSOD1 CD4+ T cell 
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recipient groups has increased Fas expression relative to WT whole splenocyte recipient 
controls. nNos expression was also increased in the mSOD1 whole splenocyte group, and 
this increase was significant relative to the mSOD1 CD4+ T cell recipients at both early and 
late post-axotomy timepoints. These findings lead us to conclude that the presence of the 
mSOD1 mutation in the peripheral immune system compartment alone can result in 
induction of central neuronal death mechanisms after peripheral nerve injury.
To confirm these results, future experiments will determine if disrupting the Fas-mediated 
death pathway blocks mSOD1 whole splenocyte-induced motoneuron death, using a similar 
approach as performed on mSOD1 mice (Raoul et al., 2006). Additionally, the cell-specific 
downstream effects of Fas-signaling will need to be examined in both mSOD1 CD4+ T cell 
and mSOD1 whole splenocyte recipients to determine the differential effects these 
immunoreconstitutions have that contribute to motoneuron survival or death.
4.6 Potential clinical applications of findings
In this study, we demonstrate that the peripheral immune system significantly regulates 
central molecular responses to peripheral nerve injury, which carries implications for future 
clinical therapies for ALS. Clinical trials targeting the immune system in ALS have largely 
focused on immunosuppression, which, as shown here, can result in loss of both the 
neuroprotective and neurotoxic effects (Kelemen et al., 1983; Brown et al., 1986; Werdelin 
et al., 1990; Drachman et al., 1994). With the mounting evidence supporting the non-cell 
autonomous theory of ALS, the results of this study lead us to hypothesize that the 
peripheral immune system may be a key contributor to motoneuron death in ALS, through 
both the induction of a neurotoxic A1 astrocyte phenotype and promotion of Fas cell death 
receptor expression in the CNS (Fig. 9). The results of this study, in combination with our 
previously published series of papers (Mesnard et al., 2010; Mesnard et al., 2011; Haulcomb 
et al., 2014), have led to the successful identification of key CNS cellular and molecular 
targets regulated by peripheral immune status in response to peripheral nerve injury. Future 
directions will include dissection of the combination of cell-cell interactions and regulatory 
pathways using genetic manipulation and protein analysis to identify clinically-relevant 
therapeutic targets.
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Highlights
• Immunodeficient mice have a suppressed glial response after facial nerve 
axotomy
• Neuroprotective WT CD4+ T cells regulate the glial microenvironment
• Intrinsic motoneuron regeneration response is independent of immune status
• mSOD1 whole splenocytes induce cell death pathways after axotomy
• New role proposed for the immune system in neurodegenerative diseases
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Figure 1. 
mRNA expression of motoneuron regeneration-associated genes in the facial motor nucleus 
following facial nerve axotomy (Ax), relative to the control (C) facial motor nucleus. Mean 
percent change ± SEM was plotted across unoperated (0) and 7, 14, 28, and 56 days post 
operative (dpo) timepoints. Symbols used: $: p < 0.05 comparing WT to RAG-2-/- + WT 
CD4+ T cells and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + WT CD4+ T cells.
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Figure 2. 
mRNA expression of glial activation-associated genes comparing the axotomized (Ax) to the 
control (C) facial motor nucleus. Mean percent change ± SEM was plotted across uninjured 
(0) and 7, 14, 28, and 56 days post-operative (dpo) timepoints. Symbols used: *: p < 0.05 
comparing WT to RAG-2-/- and #: p < 0.05 comparing RAG-2- - to RAG-2-/- + WT CD4+ T 
cells.
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Figure 3. 
Mean relative gene expression ± SEM of Tnfα compared to Gapdh in the axotomized facial 
motor nucleus (A). mRNA expression of Tnfr1 comparing the axotomized (Ax) to the 
control (C) facial motor nucleus. Mean percent change ± SEM was plotted across uninjured 
(0) and 7, 14, 28, and 56 days post-operative (dpo) timepoints (B). Symbols used: *: p < 
0.05 comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to RAG-2-/- + WT CD4+ T 
cells; and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + WT CD4+ T cells.
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Figure 4. 
mRNA expression of cell death-associated genes comparing the axotomized (Ax) to the 
control (C) facial motor nucleus. Mean percent change ± SEM was plotted across uninjured 
(0) and 7, 14, 28, and 56 days post-operative (dpo) timepoints. Symbols used: *: p < 0.05 
comparing WT to RAG-2-/-; $: p < 0.05 comparing WT to RAG-2-/- + WT CD4+ T cells; 
and #: p < 0.05 comparing RAG-2-/- to RAG-2-/- + WT CD4+ T cells.
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Figure 5. 
mRNA expression of motoneuron regeneration-associated genes in the facial motor nucleus 
following facial nerve axotomy (Ax), relative to the control (C) facial motor nucleus. Mean 
percent change ± SEM was plotted across unoperated (0) and 7, 14, 28, and 56 days post 
operative (dpo) timepoints. Symbols used: *: p < 0.05 comparing RAG-2-/- + WT whole 
splenocytes to RAG-2-/- + mSOD1 whole splenocytes; $: p < 0.05 comparing RAG-2-/- + 
WT whole splenocytes to RAG-2-/- + mSOD1 CD4+ T cells; and #: p < 0.05 comparing 
RAG-2-/- + mSOD1 whole splenocytes to RAG-2-/- + mSOD1 CD4+ T cells.
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Figure 6. 
mRNA expression of glial-associated genes in the facial motor nucleus following facial 
nerve axotomy (Ax), relative to the control (C) facial motor nucleus. Mean percent change ± 
SEM was plotted across unoperated (0) and 7, 14, 28, and 56 days post operative (dpo) 
timepoints. Symbols used: $: p < 0.05 comparing RAG-2-/- + WT whole splenocytes to 
RAG-2-/- + mSOD1 CD4+ T cells.
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Figure 7. 
Mean relative gene expression ± SEM of Tnfα compared to Gapdh in the axotomized facial 
motor nucleus (A). mRNA expression of Tnfr1 comparing the axotomized (Ax) to the 
control (C) facial motor nucleus. Mean percent change ± SEM was plotted across uninjured 
(0) and 7, 14, 28, and 56 days post-operative (dpo) timepoints (B).
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Figure 8. 
mRNA expression of Fas/nNos cell death-associated genes in the facial motor nucleus 
following facial nerve axotomy (Ax), relative to the control (C) facial motor nucleus. Mean 
percent change ± SEM was plotted across unoperated (0) and 7, 14, 28, and 56 days post 
operative (dpo) timepoints. Symbols used: *: p < 0.05 comparing RAG-2-/- + WT whole 
splenocytes to RAG-2-/- + mSOD1 whole splenocytes; $: p < 0.05 comparing RAG-2-/- + 
WT whole splenocytes to RAG-2-/- + mSOD1 CD4+ T cells; and #: p < 0.05 comparing 
RAG-2-/- + mSOD1 whole splenocytes to RAG-2-/- + mSOD1 CD4+ T cells.
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Figure 9. 
Summary of findings from this study. On the left, WT CD4+ T cells are depicted as 
regulators of glial responses to axotomy, resulting in a neuroprotective glial 
microenvironment that promotes motoneuron survival. On the right, mSOD1 whole 
splenocytes are shown as generating a neurotoxic glial environment by promoting an 
aberrant astrocyte phenotype and increasing Fas expression, thereby contributing to greater 
motoneuron death.
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Table 1
Catalog information for qPCR TaqMan assays ordered from Thermo Fisher Scientific.
Gene TaqMan ID RefSeq Accession Number
βII-tubulin (Tubb2a) Mm00809562_s1 NM_009450.2
Fas Mm01204974_m1 NM_007987.2
Gap-43 Mm01144975_m1 NM_008083.2
Gapdh Mm99999915_g1 NM_001289726.1, NM_008084.3
Gfap Mm01253033_m1 NM_001131020.1, NM_010277.3
nNos (Nos1) Mm00435175_m1 D14552.1 (GenBank)
Tnfα Mm00443260_g1 NM_013693.3
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